ARTICLES BY ERIN HARRIS

• Inside Novome Biotechnologies’ Phase 1 Study of NOV-001

  11/22/2021

  Novome Biotechnologies recently announced positive results from a Phase 1 study of orally administered NOV-001 in healthy volunteers. The Phase 1 study demonstrated the ability to safely colonize the human gut with a therapeutically engineered microbe and control its abundance via once-daily dosing of a prebiotic control molecule. Based on these results, Novome intends to commence a Phase 2a study to evaluate preliminary efficacy in patients with enteric hyperoxaluria.

• Inside Canavan Disease With BridgeBio’s Dr. Eric David

  10/29/2021

  Canavan disease is rare genetic neurological disorder characterized by the spongy degeneration of the white matter in the brain. Affected infants may appear normal at birth, but usually develop symptoms between 3-6 months of age. According to National Organization for Rare Diseases (NORD), most affected children develop life-threatening complications by 10 years of age. Canavan disease occurs because of mutations in the aspartoacylase (ASPA) gene that affects the breakdown (metabolism) of the N-acetylaspartic acid (NNA). It is inherited as an autosomal recessive condition.

• New Discoveries For Hemophilia A

  7/30/2021

  The Mayo Clinic describes Hemophilia A as a rare, inherited disorder in which the blood doesn't clot normally, because it lacks sufficient blood-clotting proteins (clotting factors). People with hemophilia may bleed for a longer time after an injury than they would if their blood clotted normally. Hemophilia A, also known as classical hemophilia, is a genetic bleeding disorder caused by insufficient levels of a blood protein called factor VIII, which is a clotting factor.

• Cell & Gene Therapies For Parkinson’s Disease

  7/6/2021

  Emile Nuwaysir, President and CEO of BlueRock Therapeutics explains the recruitment process for the trial, the trial’s primary objective, and more.

• Tevogen Bio, BioCentriq Team Up To Manufacture T-Cell Therapy For COVID-19

  3/23/2021

  Tevogen Bio recently announced its partnership with BioCentriq, a New Jersey-based cell and gene therapy development and manufacturing center, to support clinical manufacturing of Tevogen’s investigational COVID-19 treatment. 

• Inside Omega Therapeutics’ Epigenomic Controllers™

  12/1/2020

  Omega Therapeutics is developing novel engineered and modular therapeutics, called Omega Epigenomic Controllers™, that are designed to target with high specificity and downregulate or upregulate the level of expression of any of the 25,000+ human genes, individually or collectively, with controlled durability, to treat and potentially cure disease.